Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ChIPseq analysis of patient-derived luminal breast cancer xenografts with progestins

ABSTRACT: Primary breast cancer xenografts

ORGANISM(S): Homo sapiens

PROVIDER: GSE93108 | GEO | 2017/01/04

SECONDARY ACCESSION(S): PRJNA360065

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNAseq analysis of patient-derived luminal breast cancer xenografts treated with progestins

Project description:Primary breast cancer xenografts

2017-01-04 | GSE93057 | GEO

Patient-derived luminal breast cancer xenografts with progestins

Project description:Patient-derived luminal breast cancer xenografts with progestins

| PRJNA360064 | ENA

scRNA-seq analysis of patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2022-08-12 | GSE136260 | GEO

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts Two primary xenografts with different treatments

2013-02-24 | E-GEOD-36075 | biostudies-arrayexpress

Estrogen receptor dynamics in diverse patient-derived luminal breast cancer xenografts

Project description:Primary breast cancer xenografts

2013-02-24 | GSE36075 | GEO

Patient-derived luminal breast cancer xenografts with progestins

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-01-04 | GSE93109 | GEO

Patient-derived Human Breast Cancer Xenografts

Project description:Breast cancer research is hampered by difficulties in obtaining and studying primary human breast tissue, and by the lack of in vivo preclinical models that reflect patient tumor biology accurately. To overcome these limitations, we propagated a cohort of human breast tumors grown in the epithelium-free mammary fat pad of SCID/Beige and NOD/SCID/IL2γ-receptor null (NSG) mice, under a series of transplant conditions. Both models yielded stably transplantable xenografts at comparably high rates (~23% and ~19%, respectively). Of the conditions tested, xenograft take rate was highest in the presence of a low-dose estradiol pellet. Overall, 32 stably transplantable xenograft lines were established, representing unique 25 patients. Most tumors yielding xenografts were “triple-negative” (ER-PR-HER2+) (n=19). However, we established lines from three ER-PR-HER2+ tumors, one ER+PR-HER2-, one ER+PR+HER2- and one “triple-positive” (ER+PR+HER2+) tumor. Serially passaged xenografts show biological consistency with the tumor of origin, are phenotypic stability across multiple transplant generations at the histological, transcriptomic, proteomic, and genomic levels, and show comparable treatment responses. Xenografts representing 12 patients, including two ER+ lines, showed metastasis to the mouse lung. These models thus serve as a renewable, quality-controlled tissue resource for preclinical studies investigating treatment response and metastasis. The study was designed to determine how stable patient-derived xenografts are across multiple transplant generations in mice, and to determine how closely xenografts established with pre-treatment samples cluster with xenografts established with post-treatment samples. Overall, pre-treatment and post-treatment samples derived from the same patient cluster together, and multiple transplant generations of xenografts derived from an individual patient cluster together.

2013-05-30 | E-GEOD-46106 | biostudies-arrayexpress

Patient-derived Human Breast Cancer Xenografts

2013-05-30 | GSE46106 | GEO

scRNA-seq analysis of patient-derived luminal breast cancer xenografts

Project description:scRNA-seq analysis of patient-derived luminal breast cancer xenografts

| PRJNA561776 | ENA

DNA methylation analysis of breast cancer patient-derived xenografts and organoids

Project description:To understand if the generation of xenograft and organoid models of breast cancer alters DNA methylation, we compared the genome-wide methylation profile of matching patient tumors, patient derived xenografts, and organoid cultures derived from xenografts.

2022-01-09 | GSE186747 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data